Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof

US9512185B2 · kind B2 · utility

Assignees

• XIAMEN UNIVERSITY · CN
• Xiamen Innovax Biotech Co., Ltd. · CN

Inventors

• Shaowei Li · Potomac, US
• Cuiling Song · Nanjing, CN
• Chunyan Yang · Xiamen, CN
• Ying Gu · Fujian, CN
• Wenxin Luo · Xiamen, CN
• Ningshao Xia · Fujian, CN

Key dates

• Filing date: Jun 1, 2012
• Grant date: Dec 6, 2016
• Expiry date: Jun 1, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/28134
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.